Search results for

Schering-Plough and two generic manufacturers have been charged by the US Federal Trade Commission (FTC) with conspiring to keep a generic version of the drug K-Dur 20 off the market. The FTC charged Schering with paying Upsher-Smith Labs and ESI Lederle to keep the drug off the market in an effort to maintain a monopoly on its manufacture, which is costing consumers $100 million per year.

It was the year of the dot-com bubble, and IP owners like everyone else were obsessed with the net. James Nurton and Tabitha Parker analyze some of 2000’s most interesting cases

The decision of the ECJ rejecting a ban on tobacco advertising and sponsoring was met with applause in the EU. But the European Commission now wants a pan-European prohibition of tobacco advertising in the print media, reports Henning Hartwig

BRAZIL: Merck slashed prices of two AIDS drugs, just days after threatening to take Brazil's state-owned pharmaceutical firm Far-Manguinhos to court for violating the patent on an AIDS drug. Brazil has agreed to halt its plans to challenge the patent. CHINA: Cable TV, the sole provider of pay-TV programmes in China, is urging the Chinese government to outlaw the possession of unauthorized decoders openly on sale in Shenzhen. The Broadcasting Ordinance forbids the manufacture and sale of decoders but does not forbid unauthorized viewing. CHINA: Philips Electronics is to invest $1 in a new assembly and test plant in China. CHINA: A senior manager of the Unilever group is in custody after being accused of helping a local firm to produce fake Unilever products. CHINA: The government is to pass legislation to extend copyright protection to cover the internet, and bring its legislation in to line with developed countries. CHINA: People in Hebei in China will be rewarded up to 10% of the amount of the fines imposed if they report the production or sale of fake or inferior goods to anti-counterfeiting departments. CZECH REPUBLIC: Czech brewer Budejovicky Budvar, which has a long-running trade mark dispute with Anheuser-Busch, has relinquished rights to the Budweiser name in the US. Budvar will adopt Czechvar as the brand name for its product in the American beer market. JAPAN: The first dispute over internet domain names in an Asian alphabet has ruled in favour of Japanese Pharmaceutical company Sankyo. WIPO ordered the immediate transfer of the two-character Japanese name which corresponds to sankyo.com. SWEDEN: From May 7, Skriptor, changs its name to Compu-Mark Nordic for its trade mark searching activities but will function under the Skriptor name for its name creation activities. UK: Three people were convicted for their part in a multi-million pound software counterfeit scam to defraud Microsoft. The fraudsters received jail sentences of 10 years. US: Abbott Laboratories plans to sell its two AIDS drugs at no profit in sub-Saharan Africa. The drugs will be sold for less than $1000 each. In the US they sell for $7,100. US: EMI and Bertelsmann joined together to launch a new subscription-based music service on the web called MusicNet. RealNetworks is bringing its internet media technology into the partnership. MusicNet will be available later this year. The companies will license the platform to companies wanting to sell music subscription services on the web including Napster. US: Mylan Laboratories and Watson Pharmaceuticals received approval from US regulators to market generic forms of the drug BuSpar, ending a four-month patent dispute with Bristol-Myers Squibb. US: Versign will keep the right to register dot-com names until 2007. It will give up control of dot-org after 2002 and submit dot-net for re-bidding in early 2006. The changes still need to be agreed by the US Commerce Department. US: Embattled song-swap company Napster has licensed revolutionary digital fingerprinting technology to help it filter out copyrighted songs from its service to comply with a federal court order. US: Federal antitrust enforcers are preparing civil charges against Schering-Plough and generic companies Upsher-Smith of Minneapolis, and the Lederle unit of American Home Products. Charges allege patent settlements between the companies including illegal payments of $90 million to delay a low-cost generic drug from reaching the market.

Recent changes to patent law and PTO prosecution in the US make prosecution a much more complex matter. Gregory J Maier and Philippe Signore take a close look at the reforms

Tony Samuel, in the third of three articles on intellectual property value issues, considers some of the questions arising from the enormous growth in the worth of media and sponsorship rights in sport

Fittingly, I am writing this column on April 26 ? the first World Intellectual Property Day. Today, which will become an annual celebration, is the date when the Convention establishing WIPO entered into force in 1970.

A decision of special interest to the biotechnology community, Hitzeman v Rutter, 58 USPQ 2d 1161 (Fed Cir 2001), was delivered by the United States Court of Appeals for the Federal Circuit (CAFC or Federal Circuit) on March 21. The case arose as an appeal from the US Patent and Trademark Office (PTO) Board of Appeals and Interferences and it involved a determination of who is entitled to receive a US patent covering the particulate hepatitis B surface antigen produced in yeast cells, which is an effective human vaccine against hepatitis B. Prior to this invention, it was doubted by informed scientists that satisfactory hepatitis B surface antigen for vaccine purposes could be achieved using recombinant yeast cells as host cells, since bacterial host cells transformed with DNA encoding the hepatitis B surface antigen had been shown to produce a non-particulate antigen having no capability to impart immunity to hepatitis B in humans.

A new set of amendments to the Patent Law of the People’s Republic of China will enter into force in July 2001. Elizabeth Chien-Hale examines the revisions to the compulsory licensing provisions

The Supreme Court in New Delhi has laid down guidelines to avoid the registration of deceptively similar trade marks. Saying there should be the maximum possible number of indicators to distinguish two medicinal products, the Court has drawn up a broad seven-point set of rules on the registration of trade marks for medicines.